… they may inhibit two coronavirus enzymes. This … sofosbuvir/velpatasvir combination plus
the national standard of care in adult patients hospitalized with moderate to severe COVID-19 …

… that used the combination sofosbuvir/daclastavir (SOF/DCV), the latter of which was very
similar to velpatasvir, in patients with moderate/severe COVID-19 concluded that antiviral …

… of compounds with therapeutic potential against COVID-195,6. … Sofosbuvir and Velpatasvir,
able to targeting viruses belonging to two or more viral families (as flavivirus and coronavirus …

… /daclatasvir, sofosbuvir/ledipasvir and sofosbuvir/velpatasvir, on the clinical outcomes in
patients with COVID-19… the impact of sofosbuvir-based treatment on the mortality of patients with …

… the use of sofosbuvir–velpatasvir and sofosbuvir alone, respectively, for … of sofosbuvir–daclatasvir
among patients with COVID-19 relative to non-administration of sofosbuvir–daclatasvir …

… could also be susceptible to sofosbuvir and we were … of sofosbuvir 400 mg (in combination
with velpatasvir 100 mg, as add-on treatment, in addition to standard of care) on the COVID-19…

… Available evidence suggests that sofosbuvir/daclatasvir improves survival and clinical
recovery in patients with moderate to severe COVID-19. However, the sample size for analysis …

… sofosbuvir–velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir–velpatasvir …
Serious adverse events occurred in 19% of patients who received sofosbuvir–velpatasvir for …

… the theoretical efficacy of ribavirin and sofosbuvir in the treatment of COVID-19 patients.[ 13
… sofosbuvir could be used as treatment against SARS-CoV-2 infection.[ 15 ] Also, velpatasvir …

… been found to treat COVID-19. The aim of this trial was to assess if the addition of sofosbuvir
and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19. …